Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 769

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 769
---
 with respect to distributions of assets and rights upon the occurrence of a liquidation, rank (i) senior to the Company’s common stock, and (ii) senior to any other class or series of capital stock of the Company hereafter created which does not expressly rank pari passu with, or senior to, the Series A Preferred Stock. The Series A Preferred Stock is pari passu in liquidation to the Company’s Series C Preferred Stock. The liquidation value of the Series A Preferred stock at June 30, 2024, is its stated value of $ 279(June 30, 2023 - $ 279). There was nochange to the Series A Preferred stock for the years ended June 30, 2024, or 2023. Common stock Amended articles of incorporation On June 30, 2023, the Company amended its articles of incorporation to increase the number of authorized shares of common stock from 5,500to 75,000shares. Stock issuances Year ended June 30, 2024 On September 19, 2023, the Company entered into a Sales Agreement, (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”) pursuant to which the Company may offer and sell, from time to time, through the Agent, as sales agent and/or principal, shares of common stock having an aggregate offering price of up to $ 2,850(the “ATM Facility”), subsequently increased to $ 10,900on December 18, 2023. From October 31, 2023, until June 30, 2024, the Company raised $ 10,471in net proceeds, after deducting share issuance costs of $ 435, from the sale of 53,151shares of its common stock at a weighted average price of $ 0.21per share under the ATM Facility. On February 22, 2024, the Company determined that it had concluded utilization of the ATM Facility. Sales of the shares of common stock made under the ATM Facility may be made in negotiated transactions, or by any method permitted by law that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on The Nasdaq Capital Market or sales made to or through a market maker other than on an exchange. Pursuant to the Sales Agreement, the Company has the right, in its